New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.

Vasc Health Risk Manag · 2012 · PMC3273411 · PMID 22323896

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Furthermore, dabigatran 150 mg twice daily demonstrated a statistically significant reduction in ischemic stroke (the predominant type of stroke associated with atrial fibrillation) compared with warfarin, but the reduction in ischemic stroke did not reach statistical significance with apixaban versus warfarin.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.